No recent analyst price targets found for ATTO.
Latest News for ATTO
Attovia Therapeutics Begins IPO Effort On Promising Early Trials
Attovia Therapeutics is pursuing a U.S. IPO to fund its immune-mediated disease drug pipeline, led by ATTO-1310. ATTO-1310 has shown positive preliminary Phase 1 safety and efficacy results, with rapid itch relief and lesion control in chronic pruritus and high-itch AD patients. The company is well-capitalized and backed by top-tier life science investors but will require substantial additional funding for continued…
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for ATTO.
Senate Trading
No Senate trades found for ATTO.
U.S. House Trading
No House trades found for ATTO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.